DEF: Quantum-Si Sets 2026 Annual Meeting Agenda

Quantum-Si Incorporated announces its 2026 annual meeting of stockholders to be held virtually on May 15, 2026, to vote on director elections, auditor ratification, and executive compensation.

Summary

• The 2026 annual meeting of stockholders will be held virtually on Friday, May 15, 2026, at 1:00 p.m. Eastern Time.
• Stockholders will vote to elect ten directors to serve one-year terms expiring in 2027.
• Stockholders will be asked to ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
• A non-binding, advisory vote will be held on the compensation of named executive officers, as disclosed in the proxy statement.
• The record date for stockholders entitled to vote at the annual meeting is March 20, 2026, with 216,368,773 shares of common stock outstanding.
• Dr. Jonathan M. Rothberg, Ph.D., beneficially owns 100% of Class B common stock and controls 69.33% of the total voting power, enabling him to elect directors and approve proposals.
• The company reported a Net Loss of $(101) million for the fiscal year ended December 31, 2025, consistent with the $(101) million Net Loss in 2024.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with a negative sentiment due to the continued net losses and the significant decline in the value of executive equity compensation, reflecting poor stock performance and shareholder value erosion in 2025.

Positives

• The board of directors recommends the approval of all proposals, including director elections, auditor ratification, and executive compensation.
• Despite being a 'controlled company,' Quantum-Si has opted to maintain a majority of independent directors on its board.
• The audit committee consists entirely of independent directors who meet Nasdaq Listing Rules and SEC independence requirements, with two members qualifying as audit committee financial experts.
• The compensation committee retained independent executive compensation consulting firms (AON and Meridian) to advise on executive compensation matters, affirming their independence.

Negatives

• The company reported a Net Loss of $(101) million for the fiscal year ended December 31, 2025, which is consistent with the prior year's loss, indicating continued unprofitability.
• The 'Compensation Actually Paid' for the PEO (Jeffrey Hawkins) was a negative $(2,912,443) in 2025, primarily due to a significant decrease in the fair value of outstanding and unvested equity awards.
• The average 'Compensation Actually Paid' for non-PEO NEOs decreased substantially from $3,395,764 in 2024 to $420,514 in 2025, also driven by negative changes in equity award fair values.
• The Total Shareholder Return (TSR) for an initial $100 investment declined to $60.11 in 2025, indicating a significant loss in shareholder value over the period.

Risks

• The company's 'controlled company' status, due to Dr. Jonathan M. Rothberg's majority voting power, allows it to elect not to comply with certain Nasdaq corporate governance standards, potentially reducing independent oversight.
• Reliance on Dr. Rothberg's controlling interest means he has the power to elect each of the nominees, ratify the auditor, and approve executive compensation, concentrating decision-making power.
• Potential for conflicts of interest exists due to related party transactions, such as lease arrangements and a Master Services Agreement with 4C, an entity related to Dr. Rothberg's sibling.
• Executive and director equity compensation awards are tied to stock price performance, making compensation volatile and potentially misaligned if the stock price continues to decline, as suggested by the negative 'Compensation Actually Paid' figures.

Future Outlook

This proxy statement primarily focuses on corporate governance matters, executive compensation disclosures for past periods, and proposals for the upcoming annual meeting. It does not contain explicit forward-looking statements or guidance regarding the company's future operational or financial performance beyond the fiscal year 2026 auditor appointment.

Management Comments

• "We hope you will be able to attend the annual meeting. Whether or not you plan to attend the annual meeting, we hope you will vote promptly."
• "Thank you for your continued support of Quantum-Si Incorporated. We look forward to seeing you at the annual meeting."

Industry Context

StockSavvy.ai notes that the virtual format for the annual meeting aligns with a broader industry trend towards digital engagement and cost efficiency, especially for companies in the life sciences and technology sectors. The company's focus on executive compensation and governance, including the use of independent compensation consultants, reflects standard practices for publicly traded biotechnology firms navigating complex regulatory environments. The continued net losses, while not ideal, are not uncommon for early-stage or growth-focused biotechnology companies investing heavily in R&D and market penetration.

Comparison to Industry Standards

• The virtual annual meeting format is consistent with many public companies, particularly in the tech and biotech sectors, aiming for broader stockholder participation and reduced logistical costs.
• The use of PricewaterhouseCoopers LLP as the independent registered public accounting firm is standard for a company of this size and public status, comparable to practices at other Nasdaq-listed life sciences companies.
• The 'controlled company' status, while permissible under Nasdaq rules, is a deviation from the standard corporate governance benchmark of a fully independent board majority, though the company states it has opted to maintain a majority of independent directors.
• The executive compensation structure, including performance-based stock options with specific stock price targets ($6, $8, $10, $12), is a common incentive mechanism in the biotech industry, similar to those seen in companies like Illumina or GenMark Diagnostics, aiming to align management incentives with shareholder value creation. However, the significant negative 'Compensation Actually Paid' for PEO and non-PEO NEOs in 2025, driven by declining equity award values, suggests that these targets may not have been met or the stock price has underperformed relative to grant date values.

Management Changes

Corporate Governance

Legal Proceedings

• There are no legal proceedings to which any of our directors or executive officers is a party adverse to us or our subsidiary or in which any such person has a material interest adverse to us or our subsidiary.

Related Party Transactions

• Lease arrangements for office spaces at 485 Old Whitfield Street, Guilford, Connecticut, were with Oceanco, LLC, where Michael Rothberg (Dr. Jonathan M. Rothberg's sibling) is the sole stockholder.
• A Master Services Agreement (MSA) with 4C, an entity related to Michael Rothberg, for services such as general administration, facilities, information technology, financing, legal, and human resources. Payments to 4C were $276,000 for services in 2024 and immaterial amounts in 2025.

Stakeholder Impact

• Shareholders: Will directly vote on key governance matters, including director elections, auditor ratification, and executive compensation. The 'controlled company' status means Dr. Rothberg's vote is decisive on these matters. Continued net losses and negative TSR in 2025 indicate a negative impact on shareholder value.
• Employees: Executive compensation plans and severance policies provide incentives and security for key management personnel.
• Customers/Suppliers: No direct impact on customers or suppliers is mentioned in this governance-focused filing.

Next Steps

• Stockholders are invited to attend and vote at the virtual annual meeting on May 15, 2026.
• The company will publish preliminary or final voting results in a Current Report on Form 8-K within four business days of the annual meeting.
• The audit committee will reconsider its selection of PricewaterhouseCoopers LLP if stockholders do not ratify the appointment.
• The compensation committee and board of directors will review the voting results of the advisory executive compensation vote when making future decisions.
• Stockholders can submit proposals for inclusion in the 2027 annual meeting proxy statement by December 2, 2026.
• Stockholders can submit proposals for presentation at the 2027 annual meeting (not for proxy statement inclusion) between January 15, 2027, and February 15, 2027.
• Stockholders intending to solicit proxies for director nominees for the 2027 annual meeting must provide notice by March 16, 2027.

Key Dates

Recommendation

This filing is a routine proxy statement for an annual meeting, primarily focused on corporate governance, executive compensation disclosures for past periods, and proposals for future votes. It does not contain new operational or financial results that would significantly alter the investment thesis. While the company reported continued net losses and negative Total Shareholder Return in 2025, these are disclosures related to past performance and governance, not new catalysts. The 'controlled company' status and related party transactions are noted but are not new information. Investors should hold and await future operational and financial updates.

Keywords

Quantum-Si, QSI, Proxy Statement, Annual Meeting, Corporate Governance, Executive Compensation, Board of Directors, Auditor Ratification, SEC Filing, Biotechnology, Life Sciences, Stockholder Vote, DEF 14A